Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selected drugs that inhibit DNA methylation can preferentially kill p53 deficient cells.

Oncotarget - 15 Oct 2014

Yi Lan, Sun Yvonne, Levine Arnold

Abstract excerpt

The p53 protein ensures cellular fidelity by suppressing or killing cells under stresses that enhance the mutation rate. Evidence suggests that the p53 protein may also ensure the fidelity of the epigenome. In this study a group of drugs that alter the deoxycytosine methylation patterns in cellular DNA are shown to preferentially kill human and mouse cells that contain p53 mutations or deficiencies. These...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticarcinogenic Agents
Share to Azacitidine
Share to Catechin

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytidine

Share to Decitabine

Share to Neoplasm Transplantation

Share to Phthalimides

Share to Tryptophan

Source

Open in PubMed Open full text

Identifiers

PMID: 25238040
DOI: 10.18632/oncotarget.2441
PMCID: PMC4253407

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selected drugs that inhibit DNA methylation can preferentially kill p53 deficient cells.PMID 25238040Read ↗

The p53 protein plays a central role in the mechanism of action of epigentic drugs that alter the methylation of cytosine residues in DNA.Semantic proximity Read ↗

Targeting Therapies for the p53 Protein in Cancer TreatmentsSemantic proximity Read ↗

Identification of Novel p53 Pathway Activating Small-Molecule Compounds Reveals Unexpected Similarities with Known Therapeutic AgentsSemantic proximity Read ↗

Small molecule compounds targeting the p53 pathway: are we finally making progress?Semantic proximity Read ↗

Therapeutic exploitation of the p53 pathway.Semantic proximity Read ↗

A new family of small molecules to probe the reactivation of mutant p53.Semantic proximity Read ↗

Twenty years of Gendicine® rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncologySemantic proximity Read ↗

2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells.Semantic proximity Read ↗

Suppression of mismatched mutation by p53: a mechanism for guarding genomic integrity.Semantic proximity Read ↗

Interference with p53 functions in human viral infections, a target for novel antiviral strategies?Semantic proximity Read ↗

Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors.Semantic proximity Read ↗

The dual role of mutant p53 protein in chemosensitivity of human cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.